Gustavo Baretton
Overview
Explore the profile of Gustavo Baretton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
1934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong F, Merker S, Bauer L, Han Y, Le V, Wenzel C, et al.
Br J Cancer
. 2025 Jan;
132(4):326-339.
PMID: 39863771
Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits a high frequency of neural invasion (NI). Schwann cells (SCs) have been shown to be reprogrammed to facilitate cancer cell migration and invasion into...
2.
Hommerding O, Bernhardt M, Kreft T, Scherping A, Abbas M, Baretton G, et al.
Virchows Arch
. 2024 Dec;
PMID: 39653828
The prognostication of individual disease trajectory and selection of optimal therapy in patients with localized, low-grade prostate cancer often presents significant difficulty. The phosphatase and tensin homolog on chromosome 10...
3.
Grutzmann K, Salomo K, Kruger A, Lohse-Fischer A, Erdmann K, Seifert M, et al.
Biol Direct
. 2024 May;
19(1):38.
PMID: 38741178
Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC with high rates of metastasis. Targeted therapies such as tyrosine kinase and checkpoint inhibitors have improved...
4.
Grimm M, Schostak M, Grun C, Loidl W, Pichler M, Zimmermann U, et al.
JAMA Oncol
. 2024 May;
10(6):755-764.
PMID: 38722641
Importance: Studies with nivolumab, an approved therapy for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy, demonstrate improved outcomes with added high-dose ipilimumab. Objective: To assess efficacy and safety of a...
5.
Kutz O, Drukewitz S, Kruger A, Aust D, William D, Oster S, et al.
Clin Chem Lab Med
. 2024 Apr;
62(10):2070-2081.
PMID: 38577791
Objectives: We analysed whether temporal heterogeneity of ctDNA encodes evolutionary patterns in ovarian cancer. Methods: Targeted sequencing of 275 cancer-associated genes was performed in a primary tumor biopsy and in...
6.
Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300348.
PMID: 38513168
Purpose: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency...
7.
Borkowetz A, Sommer U, Baretton G, Gruellich C, Burk B, Erb H, et al.
World J Urol
. 2024 Feb;
42(1):94.
PMID: 38386122
Purpose: Cabozantinib (CAB) as monotherapy or in combination with immune checkpoint inhibitors is used for systemic treatment of metastatic renal cell carcinoma (mRCC). However, little is known about predictors of...
8.
Ruschoff J, Schildhaus H, Ruschoff J, Johrens K, Bocker Edmonston T, Dietmaier W, et al.
Pathologie (Heidelb)
. 2023 Oct;
44(Suppl 2):61-70.
PMID: 37874379
Testing to detect mismatch repair deficiency (dMMR) and high-grade microsatellite instability (MSI-H) has become an integral part of the routine diagnostic workup for colorectal cancer (CRC). While MSI was initially...
9.
Grimm M, Esteban E, Barthelemy P, Schmidinger M, Busch J, Valderrama B, et al.
Lancet Oncol
. 2023 Oct;
24(11):1252-1265.
PMID: 37844597
Background: Nivolumab plus ipilimumab is approved as first-line regimen for intermediate-risk or poor-risk metastatic renal cell carcinoma, and nivolumab monotherapy as second-line therapy for all risk groups. We aimed to...
10.
Wurm A, Brilloff S, Kolovich S, Schafer S, Rahimian E, Kufrin V, et al.
Cell Rep Med
. 2023 Sep;
4(10):101200.
PMID: 37734378
Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation on...